Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / COMMON-STOCK
-
Shares outstanding
-
72.2M
-
Number of holders
-
107
-
Total 13F shares, excl. options
-
67M
-
Shares change
-
+2.73M
-
Total reported value, excl. options
-
$1.15B
-
Value change
-
+$45.9M
-
Put/Call ratio
-
1.92
-
Number of buys
-
53
-
Number of sells
-
-40
-
Price
-
$17.20
Significant Holders of Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) as of Q1 2023
118 filings reported holding ZNTL - Zentalis Pharmaceuticals, Inc. - COMMON-STOCK as of Q1 2023.
Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) has 107 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 67M shares
of 72.2M outstanding shares and own 92.8% of the company stock.
Largest 10 shareholders include Matrix Capital Management Company, LP (9.2M shares), FMR LLC (8.91M shares), VANGUARD GROUP INC (4.24M shares), BlackRock Inc. (3.42M shares), WELLINGTON MANAGEMENT GROUP LLP (3.36M shares), EVENTIDE ASSET MANAGEMENT, LLC (3.23M shares), Capital International Investors (3.13M shares), Avidity Partners Management LP (2.93M shares), STATE STREET CORP (2.83M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (2.2M shares).
This table shows the top 107 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.